Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy
Premium
Investigators showed that patients who are positive for ctDNA at the time of their fourth induction treatment have poorer outcomes and could benefit from new strategies.
Invitae Publishes First Validation Data on MRD Assays, Laying Path to Future Clinical Expansion
Premium
The analytical validity study is the first published featuring full performance data for the firm's Personalized Cancer Monitoring technology.
Single-Cell MRD Assay Helps Characterize Cells Surviving Acute Myeloid Leukemia Therapy
Researchers came up with a single-cell DNA sequencing and immunophenotyping assay for identifying and characterizing AML clones that persist after treatment.
Myriad Genetics, Memorial Sloan Kettering Partner to Study MRD Testing in Breast Cancer
The collaborators will evaluate the use of Myriad's MRD platform in predicting response to CDK4/6 inhibitors and in a chemotherapy neoadjuvant setting.
The company realized Q2 revenues from a recent surge in carrier testing volumes and expressed confidence in the potential inclusion of MRD testing in NCCN guidelines.